Jupiter Life Lin

Jupiter Life Line Hospitals is actively pursuing its initial objective to establish 2,500 beds and expand its network from 3 to 6 hospitals in Western India, a target now 'within sight.' The company has commissioned 78 new beds at its Indore facility on January 1, 2025, and is progressing with greenfield projects in Dombivli and Pune, each planned for 500 beds. Dombivli is expected to be commissioned in Q1 FY27, while Pune's construction will commence post-monsoon, following receipt of all environmental clearances.

For the full financial year 2025, Jupiter Life Line Hospitals reported a total income of INR 1,261.5 crores, marking a 17.5% year-on-year growth. EBITDA for the year increased by 22.5% to INR 296.6 crores, achieving an EBITDA margin of 23.5%. The Average Revenue Per Occupied Bed (ARPOB) also saw a significant increase of 10.4% to INR 60,600, reflecting strong operational efficiency. Overall volume grew 11.2% to 9.8 lakhs in FY25, with an average occupancy of 65.3%.

The company has strategically raised additional debt to fund new projects and optimize growth. Its Indore subsidiary (JHPPL) secured INR 250 crores debt to repay an intercompany loan, making funds available for the listed entity. Additionally, the listed entity has a sanctioned loan of INR 350 crores for capex, with INR 75 crores already drawn and the remaining INR 275 crores available. This proactive approach has resulted in a strong cash position of approximately INR 600 crores, comprising INR 325 crores from new debt and INR 275 crores from existing reserves, with the cost of carrying the new loan expected to be less than 1%.

Beyond new projects, Jupiter is investing in brownfield expansions and infrastructure upgrades. The Thane facility received approval for potential FSI increase, allowing for an additional floor, pending environmental clearances. Interim capex at Thane included reconfiguring a 22-bed economy ward to create two new operating theaters, a second MRI machine, a second cardiac cath lab, and expanding daycare/chemo suites from 14 to 22 beds, alongside a new OPD cluster and an overhaul of ageing engineering infrastructure like chillers and cooling towers.

The average occupancy for FY25 stood at 65.3%, an improvement of 150 basis points year-on-year, with Thane at 72.1%, Pune at 65.5%, and Indore at 54.9%. While ARPOB growth for mature hospitals like Thane and Pune is expected to align with inflation going forward^⏳, Indore may see slightly higher growth for another year due to case mix optimization. Q4 FY25 occupancy for Indore was 42.1%, a temporary dilution effect due to the recent commissioning of 78 new beds, and further expansion will be considered when occupancy reaches 60-65%.

The company remains open to both greenfield and strategic acquisition opportunities, provided they meet criteria such as being in Western India, aligning with a full-service flagship hub model, and offering good value for quality assets. Management emphasized that there is 'absolute clarity' that they will not expand beyond Western India for now, prioritizing sensible acquisitions over a 'mindless race to add numbers and add speed.' The focus remains on full-service tertiary care, not just satellite OPD expansion.